Source comparison
MK-677 for Bone Density: Dosing Comparison
10 mg daily +39% from baseline Osteocalcin +12–18%; modest formation signal 5–8% mild edema Exploratory research; dose-finding studies Submaximal efficacy. Insufficient for clinically meaningful BMD change in 12-month trials 25 mg daily +89% from baseline Oste
This comparison does not assign a generated winner or score.
- 10 mg daily
- +39% from baseline
- Osteocalcin +12–18%; modest formation signal
- 5–8% mild edema
- Exploratory research; dose-finding studies
- Submaximal efficacy. Insufficient for clinically meaningful BMD change in 12-month trials
- 25 mg daily
- +89% from baseline
- Osteocalcin +22–30%; PINP +18–25%; robust anabolic signal
- 15–20% mild edema; fasting glucose +8 mg/dL
- Standard research dose in bone density trials
- Optimal balance. Top of dose-response curve with acceptable tolerability
- 50 mg daily
- +95% from baseline
- Similar to 25mg (no proportional gain)
- 30–35% edema; glucose +12 mg/dL; increased appetite
- Rarely used; dose-ceiling studies only
- Minimal additional efficacy vs 25mg; higher adverse event burden. Not recommended